BIO-TECHNE Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TECH in the last 30 days.
See all $TECH insider activity →Bio-Techne faces a shareholder lawsuit and demand letters challenging its proxy disclosures for the pending acquisition by Merck KGaA. The lawsuit seeks to halt the shareholder vote scheduled for September 23, 2026. Bio-Techne plans to supplement the proxy with additional disclosures on the sale process and financial advisor details, which may impact investor assessment of the deal.
Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.
Bio-Techne (TECH) reported flat earnings, trading at $72.35. Avantor (AVTR) beat estimates with $1.69B revenue, up 17.4%. Bruker (BRKR) missed expectations, down 11.1%. Sotera Health (SHC) reported $321.4M revenue, up 7.2%. Thermo Fisher (TMO) beat estimates with $11.99B revenue, up 18.3%.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TECH (BIO-TECHNE Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent TECH coverage spans mergers & acquisitions, earnings and financial news.
Potential delay or cancellation of the merger could depress TECH stock and create volatility ahead of the September 23 vote.
Modest beat with limited price reaction.
Earnings release with flat price suggests neutral market reaction.
Merck KGaA has proposed to acquire Bio-Techne Corp. for an undisclosed amount. The deal, announced June 25, 2026, is expected to close by late 2026 or early 2027. Bio-Techne is a leader in proteins and immunoassays for academic, biopharmaceutical, and diagnostic markets.
Potential closing of a large pharma‑life‑science merger.
AlphAI scores every news story that mentions TECH with an AI model for sentiment and relevance, and aggregates insider trades from BIO-TECHNE Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bio-Techne faces a shareholder lawsuit and demand letters challenging its proxy disclosures for the pending acquisition by Merck KGaA. The lawsuit seeks to halt the shareholder vote scheduled for September 23, 2026. Bio-Techne plans to supplement the proxy with additional disclosures on the sale process and financial advisor details, which may impact investor assessment of the deal.
2 min readBruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.
3 min readBio-Techne (TECH) reported flat earnings, trading at $72.35. Avantor (AVTR) beat estimates with $1.69B revenue, up 17.4%. Bruker (BRKR) missed expectations, down 11.1%. Sotera Health (SHC) reported $321.4M revenue, up 7.2%. Thermo Fisher (TMO) beat estimates with $11.99B revenue, up 18.3%.
3 min readMerck KGaA has proposed to acquire Bio-Techne Corp. for an undisclosed amount. The deal, announced June 25, 2026, is expected to close by late 2026 or early 2027. Bio-Techne is a leader in proteins and immunoassays for academic, biopharmaceutical, and diagnostic markets.
1 min readBio-Techne has extended the deadline for its $11.3B acquisition of Merck, refiling its intent to merge to allow the FTC more time for review. The life science tool company aims to complete the deal with the pharmaceutical giant.
1 min readAnalysts covering Bio-Techne (TECH) have a consensus 'Hold' rating, with one 'Strong Buy' and one 'Strong Sell' among 15. This is less bullish than a month ago. Wells Fargo downgraded TECH to 'Equal Weight' with a $73 price target, above the mean target of $70.46. TECH trades above this average.
1 min readAvantor (AVTR) reported Q2 revenue of $1.69B, flat YoY, beating estimates by 4.9%, with stock up 8.2%. Bruker (BRKR) reported $838.5M revenue, up 5.2% YoY, missing estimates by 1.9%, with stock down 11.6%. Sotera Health (SHC) reported $321.4M revenue, up 9.2% YoY, beating estimates by 3.8%, with stock up 2.9%. Bio-Techne (TECH) reported $321.2M revenue, up 1.3% YoY, beating estimates by 2%, with stock flat.
3 min readGermany’s Bundeskartellamt cleared Merck’s planned acquisition of Bio-Techne in the first phase of merger control, saying the firms’ activities are largely complementary and overlaps do not raise major competition concerns. Merck offered $73 per Bio-Techne share, valuing it at about $11.3B (€9.9B). Remaining approvals are needed; closing expected late 2026 or early 2027.
4 min readBio-Techne (TECH) reported fiscal Q4 adjusted EPS of 52 cents, in line with the Zacks Consensus and down 1.9% year over year. Net sales were $321.2M, up 1% (3% organic) and 1.26% above estimates. Full-year adjusted EPS was $1.93. Shares rose to $72.23. TECH is also being acquired by Merck KGaA for $73/share.
6 min readBio-Techne (NASDAQ: TECH) corrected its dividend announcement. The shareholder of record date was misstated as Aug. 17, 2026 and is now Aug. 24, 2026. The company will pay a quarterly dividend of $0.08 per share for the quarter ended June 30, 2026, payable Aug. 28, 2026.
2 min read
